vs
Ginkgo Bioworks Holdings, Inc.（DNA）与PDF SOLUTIONS INC（PDFS）财务数据对比。点击上方公司名可切换其他公司
PDF SOLUTIONS INC的季度营收约是Ginkgo Bioworks Holdings, Inc.的1.9倍（$62.4M vs $33.4M），PDF SOLUTIONS INC同比增速更快（24.6% vs -23.8%），PDF SOLUTIONS INC自由现金流更多（$7.5M vs $-47.7M），过去两年PDF SOLUTIONS INC的营收复合增速更高（22.9% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
PDF Solutions Inc是一家总部位于美国加利福尼亚州圣克拉拉的跨国企业，主营软件业务与工程技术服务，目前在纳斯达克交易所挂牌上市，股票代码为PDFS。
DNA vs PDFS — 直观对比
营收规模更大
PDFS
是对方的1.9倍
$33.4M
营收增速更快
PDFS
高出48.4%
-23.8%
自由现金流更多
PDFS
多$55.2M
$-47.7M
两年增速更快
PDFS
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $62.4M |
| 净利润 | — | $-48.0K |
| 毛利率 | — | 72.9% |
| 营业利润率 | -211.9% | 5.5% |
| 净利率 | — | -0.1% |
| 营收同比 | -23.8% | 24.6% |
| 净利润同比 | — | -108.9% |
| 每股收益（稀释后） | $-1.41 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNAPDFS
| Q4 25 | $33.4M | $62.4M | ||
| Q3 25 | $38.8M | $57.1M | ||
| Q2 25 | $49.6M | $51.7M | ||
| Q1 25 | $48.3M | $47.8M | ||
| Q4 24 | $43.8M | $50.1M | ||
| Q3 24 | $89.0M | $46.4M | ||
| Q2 24 | $56.2M | $41.7M | ||
| Q1 24 | $37.9M | $41.3M |
净利润DNAPDFS
| Q4 25 | — | $-48.0K | ||
| Q3 25 | $-80.8M | $1.3M | ||
| Q2 25 | $-60.3M | $1.1M | ||
| Q1 25 | $-91.0M | $-3.0M | ||
| Q4 24 | — | $539.0K | ||
| Q3 24 | $-56.4M | $2.2M | ||
| Q2 24 | $-217.2M | $1.7M | ||
| Q1 24 | $-165.9M | $-393.0K |
毛利率DNAPDFS
| Q4 25 | — | 72.9% | ||
| Q3 25 | — | 72.3% | ||
| Q2 25 | — | 71.2% | ||
| Q1 25 | — | 72.9% | ||
| Q4 24 | — | 68.3% | ||
| Q3 24 | — | 73.1% | ||
| Q2 24 | — | 70.6% | ||
| Q1 24 | — | 67.3% |
营业利润率DNAPDFS
| Q4 25 | -211.9% | 5.5% | ||
| Q3 25 | -231.8% | 8.5% | ||
| Q2 25 | -132.1% | 2.2% | ||
| Q1 25 | -184.1% | -7.4% | ||
| Q4 24 | -236.3% | 1.0% | ||
| Q3 24 | -62.0% | 4.6% | ||
| Q2 24 | -396.7% | 0.6% | ||
| Q1 24 | -469.1% | -4.7% |
净利率DNAPDFS
| Q4 25 | — | -0.1% | ||
| Q3 25 | -207.9% | 2.3% | ||
| Q2 25 | -121.6% | 2.2% | ||
| Q1 25 | -188.2% | -6.3% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | -63.3% | 4.8% | ||
| Q2 24 | -386.4% | 4.1% | ||
| Q1 24 | -437.3% | -1.0% |
每股收益（稀释后）DNAPDFS
| Q4 25 | $-1.41 | $0.00 | ||
| Q3 25 | $-1.45 | $0.03 | ||
| Q2 25 | $-1.10 | $0.03 | ||
| Q1 25 | $-1.68 | $-0.08 | ||
| Q4 24 | $-1.91 | $0.01 | ||
| Q3 24 | $-1.08 | $0.06 | ||
| Q2 24 | $-4.23 | $0.04 | ||
| Q1 24 | $-3.32 | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | $42.2M |
| 总债务越低越好 | — | $67.0M |
| 股东权益账面价值 | $508.6M | $271.0M |
| 总资产 | $1.1B | $418.7M |
| 负债/权益比越低杠杆越低 | — | 0.25× |
8季度趋势，按日历期对齐
现金及短期投资DNAPDFS
| Q4 25 | $422.6M | $42.2M | ||
| Q3 25 | $495.5M | $35.9M | ||
| Q2 25 | $559.4M | $40.4M | ||
| Q1 25 | $325.3M | $54.1M | ||
| Q4 24 | $561.6M | $114.9M | ||
| Q3 24 | $616.2M | $120.2M | ||
| Q2 24 | $730.4M | $117.9M | ||
| Q1 24 | $840.4M | $122.9M |
总债务DNAPDFS
| Q4 25 | — | $67.0M | ||
| Q3 25 | — | $67.6M | ||
| Q2 25 | — | $68.1M | ||
| Q1 25 | — | $68.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益DNAPDFS
| Q4 25 | $508.6M | $271.0M | ||
| Q3 25 | $559.8M | $264.4M | ||
| Q2 25 | $613.0M | $257.5M | ||
| Q1 25 | $647.4M | $249.0M | ||
| Q4 24 | $716.1M | $246.0M | ||
| Q3 24 | $797.9M | $240.5M | ||
| Q2 24 | $833.1M | $232.2M | ||
| Q1 24 | $987.3M | $225.4M |
总资产DNAPDFS
| Q4 25 | $1.1B | $418.7M | ||
| Q3 25 | $1.2B | $406.4M | ||
| Q2 25 | $1.2B | $391.1M | ||
| Q1 25 | $1.3B | $390.0M | ||
| Q4 24 | $1.4B | $315.3M | ||
| Q3 24 | $1.5B | $307.4M | ||
| Q2 24 | $1.6B | $298.0M | ||
| Q1 24 | $1.6B | $286.8M |
负债/权益比DNAPDFS
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | 0.26× | ||
| Q1 25 | — | 0.28× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $17.3M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $7.5M |
| 自由现金流率自由现金流/营收 | -142.8% | 12.1% |
| 资本支出强度资本支出/营收 | 0.0% | 15.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-8.6M |
8季度趋势，按日历期对齐
经营现金流DNAPDFS
| Q4 25 | $-47.7M | $17.3M | ||
| Q3 25 | $-31.6M | $3.3M | ||
| Q2 25 | $-40.3M | $-5.2M | ||
| Q1 25 | $-51.5M | $8.6M | ||
| Q4 24 | $-42.4M | $1.6M | ||
| Q3 24 | $-103.5M | $9.3M | ||
| Q2 24 | $-84.4M | $684.0K | ||
| Q1 24 | $-89.3M | $-1.9M |
自由现金流DNAPDFS
| Q4 25 | $-47.7M | $7.5M | ||
| Q3 25 | — | $-2.9M | ||
| Q2 25 | $-40.3M | $-13.8M | ||
| Q1 25 | $-59.1M | $535.0K | ||
| Q4 24 | $-56.1M | $-4.0M | ||
| Q3 24 | $-118.6M | $5.1M | ||
| Q2 24 | $-111.4M | $-4.6M | ||
| Q1 24 | $-96.0M | $-3.9M |
自由现金流率DNAPDFS
| Q4 25 | -142.8% | 12.1% | ||
| Q3 25 | — | -5.1% | ||
| Q2 25 | -81.2% | -26.6% | ||
| Q1 25 | -122.4% | 1.1% | ||
| Q4 24 | -128.0% | -8.0% | ||
| Q3 24 | -133.2% | 11.0% | ||
| Q2 24 | -198.2% | -11.1% | ||
| Q1 24 | -252.9% | -9.4% |
资本支出强度DNAPDFS
| Q4 25 | 0.0% | 15.7% | ||
| Q3 25 | 0.0% | 10.8% | ||
| Q2 25 | 0.1% | 16.5% | ||
| Q1 25 | 15.8% | 17.0% | ||
| Q4 24 | 31.3% | 11.3% | ||
| Q3 24 | 16.9% | 9.0% | ||
| Q2 24 | 48.1% | 12.8% | ||
| Q1 24 | 17.7% | 4.9% |
现金转化率DNAPDFS
| Q4 25 | — | — | ||
| Q3 25 | — | 2.54× | ||
| Q2 25 | — | -4.55× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.98× | ||
| Q3 24 | — | 4.20× | ||
| Q2 24 | — | 0.40× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
PDFS
| Volumebased | $38.0M | 61% |
| Other | $24.4M | 39% |
